Bemethyl
Bemitil — 2-ethylthiobenzimidazole
Bemethyl (Bemitil — 2-ethylthiobenzimidazole) is a performance & endurance research compound. A Russian 'actinoprotector' — the drug class built around improving tolerance to physical work under hypoxia. Its described action is on mitochondrial protein synthesis: rather than stimulating output acutely like a beta-agonist, it is reported to raise the enzymatic capacity for gluconeogenesis and aerobic metabolism over a course of days, which is why it is dosed as a course rather than pre-workout.
Bemethyl quick facts
| Route | Oral |
| Frequency | 1-2x Daily |
| Half-life | Not well characterised in English-language sources |
| Forms | Oral |
| Evidence level | Human (Russian/Soviet clinical literature); almost none of it replicated outside that school |
Same evidence problem as the Khavinson bioregulators: decades of Russian-language use, single-group studies, and essentially no independent replication. That is not the same as 'it does not work' — it is an absence of the evidence that would settle it either way. DA sells it as a 100MG/ML 30ML liquid.
How Bemethyl works
A Russian 'actinoprotector' — the drug class built around improving tolerance to physical work under hypoxia. Its described action is on mitochondrial protein synthesis: rather than stimulating output acutely like a beta-agonist, it is reported to raise the enzymatic capacity for gluconeogenesis and aerobic metabolism over a course of days, which is why it is dosed as a course rather than pre-workout.
✅ Clinically validated
- Russian and Soviet clinical literature, where it is classed as an 'actinoprotector' — a drug category that essentially does not exist outside that research tradition. Studied for physical work capacity, hypoxia tolerance and recovery, typically at 250-500mg.
- Almost none of it has been replicated independently. Single-group designs, one research school, one language. See [[evidence-framing-rule]] — that is an absence of evidence, not evidence of absence, and the two get confused constantly with this class.
📊 Correlative data
- It sits in the same evidence position as the Khavinson bioregulators already in the Vault: decades of use inside one system, and a near-total gap in the Western literature. Read it the same way.
🧪 Theoretical / extrapolated
- Described as acting on mitochondrial protein synthesis — raising the enzymatic capacity for gluconeogenesis and aerobic metabolism rather than stimulating output acutely.
- That is why it is dosed as a course, not pre-workout. If the mechanism is adaptive rather than stimulant, a single dose before training is the wrong way to use it and the wrong way to judge whether it worked.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Bemethyl — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- It is a benzimidazole whose described action is on mitochondrial protein synthesis — raising the enzymatic capacity for gluconeogenesis and aerobic metabolism over a course of days rather than stimulating output acutely. Two things follow from that shape. The effect is a course effect, so the course is also the exposure — this is not a compound where a single bad day can be undone by skipping the next dose. And upregulating gluconeogenic capacity is a liver-side change, which is where a benzimidazole would be expected to declare a problem first.
- GI irritation — epigastric discomfort and nausea — is the complaint that recurs in the Russian-language literature.
- The honest structural warning: an actoprotector's entire selling point is raising tolerance to work under hypoxia. Raising your tolerance for a stressor is not the same as raising your capacity to survive it. Anything that makes hard work feel more sustainable has removed a signal you would otherwise have used to stop, and that is a real hazard in exactly the population that buys it.
What has actually been reported
- Decades of Soviet and Russian clinical use with reported outcomes, almost none of it independently replicated, and none of it collected in a modern adverse-event reporting system. That combination is unusual and worth naming precisely: this compound is neither 'untested' nor 'characterised'. Treat the absence of Western safety data as an absence of looking, not as a clean record.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Run it as a course and then stop. Its own pharmacology is course-based even in the literature that does exist, so continuous use is not a more committed version of the protocol — it is a different protocol nobody has studied.
- Bracket the course with the liver panel above. One test before, one after, and the compound stops being invisible.
- Take it with food if GI complaints appear; that is the standard and adequate answer to the standard complaint.
- Do not use it to extend sessions past the point where you would otherwise have stopped. Use it to recover the capacity for the sessions you were already doing.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- A liver panel — ALT, AST, GGT and bilirubin — before a course and again after it. This is the cheapest possible test of the predicted problem, and running it turns an unmeasurable compound into a partially measurable one.
Don't run this if
- Existing liver disease, or concurrent use of anything else carrying a hepatic signal.
- You are reaching for it to push through something your body is telling you to stop doing. That is the use case its mechanism most readily enables and the one it is least able to make safe.
The honest unknown
- Interaction data does not exist in any form a Western prescriber would recognise. That is a specific gap rather than a general disclaimer: there is no source to check, so nothing can be ruled out by checking one.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get Bemethyl
Buy Bemethyl at Disguised Alpha →Bemethyl — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Bemethyl moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Bemethyl — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
Get the complete breakdown for Bemethyl — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside Bemethyl
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| Comprehensive Metabolic Panel (CMP) | Liver, kidney, electrolytes and glucose in one |
| Complete Blood Count (CBC) with Differential | Broad screen for anything unexpected |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Inflammation baseline |
The The Basics — Start Here panel covers these in one order — 4 markers, $32.40 with the discount applied.
Check results you already have → · All 102 markers A–Z
Bemethyl — frequently asked questions
What is Bemethyl?
Bemethyl (Bemitil — 2-ethylthiobenzimidazole) is a performance & endurance research compound. A Russian 'actinoprotector' — the drug class built around improving tolerance to physical work under hypoxia. Its described action is on mitochondrial protein synthesis: rather than stimulating output acutely like a beta-agonist, it is reported to raise the enzymatic capacity for gluconeogenesis and aerobic metabolism over a course of days, which is why it is dosed as a course rather than pre-workout.
Where can I find Bemethyl dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Bemethyl protocol are available to members inside the Academy. This public page covers what Bemethyl is, how it works and the evidence.
What is the half-life of Bemethyl?
Bemethyl has an approximate half-life of Not well characterised in English-language sources, which is part of what determines how often it's dosed.
What's the evidence behind Bemethyl?
Current evidence level: Human (Russian/Soviet clinical literature); almost none of it replicated outside that school. Bemethyl is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact Bemethyl protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →